Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for prostate cancer

D Hrouda1, A G Dalgleish

  • 1Department of Oncology, St George's Hospital Medical School, London, UK.

Gene Therapy
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and adverse events of urgent elective surgery during COVID-19 within three UK hospitals.

The British journal of surgery·2021
Same author

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020
Same author

A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging.

The Journal of urology·2020
Same author

BK Virus Associated Haemorrhagic Cystitis. A systematic review of current prevention and treatment strategies.

International journal of surgery (London, England)·2019
Same author

A prospective clinical, cost and environmental analysis of a clinician-led virtual urology clinic.

Annals of the Royal College of Surgeons of England·2018
Same author

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.

Oncoimmunology·2018

Gene therapy offers new hope for advanced prostate cancer, a leading cause of cancer death. Both ex vivo and in vivo approaches are showing promise in preclinical studies and early human trials.

Area of Science:

  • Oncology
  • Gene Therapy
  • Cancer Research

Background:

  • Prostate cancer is a major cause of cancer mortality in Western countries.
  • Current treatments for advanced prostate cancer have limited effectiveness.
  • Gene therapy presents novel therapeutic strategies for managing prostate cancer.

Purpose of the Study:

  • To review the potential of ex vivo and in vivo gene therapy for prostate cancer.
  • To highlight promising preclinical and early clinical findings.

Main Methods:

  • Ex vivo gene therapy using cytokine-transduced tumor cell vaccines (e.g., interleukin-2, granulocyte-macrophage colony-stimulating factor).
  • In vivo gene therapy involving tumor suppressor gene replacement, antisense strategies, and suicide gene insertion.

Related Experiment Videos

  • Evaluation of preclinical models and progression to Phase I/II clinical studies.

    • Main Results:

    • Ex vivo whole tumor cell vaccines have demonstrated significant promise in animal models.
    • In vivo gene therapy strategies, including gene correction and suicide gene therapy, show feasibility in preclinical settings.
    • Several gene therapy approaches are advancing into early-phase human clinical trials for prostate cancer patients.

    Conclusions:

    • Gene therapy, encompassing both ex vivo and in vivo modalities, represents a promising frontier in prostate cancer treatment.
    • Preclinical success and ongoing clinical trials indicate the potential of gene therapy to overcome limitations of current advanced disease therapies.
    • Further clinical investigation is warranted to establish the efficacy and safety of these gene-based approaches in patients.